LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,416,143
تعداد دریافت فایل اصل مقاله11,291,867
Damirchi, Mohammadrafi, Aghaie, Mehrdad, Sedighi, Sima, Tavassoli, Samaneh, Roshandel, Gholamreza, Hassani, Mohammadjavad, Abdolahi, Nafiseh. (1401). The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report. سامانه مدیریت نشریات علمی, 48(1), 91-97. doi: 10.30476/ijms.2022.94402.2565
Mohammadrafi Damirchi; Mehrdad Aghaie; Sima Sedighi; Samaneh Tavassoli; Gholamreza Roshandel; Mohammadjavad Hassani; Nafiseh Abdolahi. "The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report". سامانه مدیریت نشریات علمی, 48, 1, 1401, 91-97. doi: 10.30476/ijms.2022.94402.2565
Damirchi, Mohammadrafi, Aghaie, Mehrdad, Sedighi, Sima, Tavassoli, Samaneh, Roshandel, Gholamreza, Hassani, Mohammadjavad, Abdolahi, Nafiseh. (1401). 'The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report', سامانه مدیریت نشریات علمی, 48(1), pp. 91-97. doi: 10.30476/ijms.2022.94402.2565
Damirchi, Mohammadrafi, Aghaie, Mehrdad, Sedighi, Sima, Tavassoli, Samaneh, Roshandel, Gholamreza, Hassani, Mohammadjavad, Abdolahi, Nafiseh. The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report. سامانه مدیریت نشریات علمی, 1401; 48(1): 91-97. doi: 10.30476/ijms.2022.94402.2565

The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report

Iranian Journal of Medical Sciences
مقاله 12، دوره 48، شماره 1، فروردین 2023، صفحه 91-97    اصل مقاله (514.96 K)
نوع مقاله: Brief Report(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2022.94402.2565
نویسندگان
Mohammadrafi Damirchi1؛ Mehrdad Aghaie1؛ Sima Sedighi1؛ Samaneh Tavassoli1؛ Gholamreza Roshandel2؛ Mohammadjavad Hassani1؛ Nafiseh Abdolahi* 1
1Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
چکیده
Recently, due to the coronavirus disease 2019 (COVID-19) pandemic, much concern has been raised about patients with chronic diseases who may become more susceptible to the disease. The present cross-sectional study aimed to characterize the clinical course of COVID-19 in patients with systemic lupus erythematosus (SLE). In addition, a possible correlation between the immunosuppression state and the incidence of COVID-19 is investigated. In May 2020, 500 SLE patients registered in the database of Golestan Rheumatology Research Center (Golestan province, Iran) were selected for this cross-sectional study. Using a questionnaire, patients were contacted by telephone to collect data including demographic characteristics, disease status, drug use, and new clinical symptoms. Data were analyzed using SPSS software version 24.0. Of the 500 selected patients, 355 responded to the phone calls and subsequently enrolled in the study. Among the enrolled patients, 25 were classified as COVID-19 positive, including eight hospitalized patients, of which two required intensive care and subsequently died. COVID-19 incidence was significantly lower in the immunosuppressed patients (2.2% vs. 10%, P=0.01). There was no significant correlation between hydroxychloroquine consumption and the incidence of COVID-19 in SLE patients. Fever, fatigue, dyspnea, and dry cough were the most common clinical symptoms. Our results showed that COVID-19 incidence was lower in immunosuppressed than the non-immunosuppressed SLE patients. Further studies are required to substantiate the role of immunosuppression in the development of COVID-19.
A preprint version of this study was published at https://www.researchsquare.com/article/rs-78704/v1 with doi: https://doi.org/10.21203/rs.3.rs-78704/v1
کلیدواژه‌ها
COVID-19؛ Systemic lupus erythematosus؛ Hydroxychloroquine؛ Immunosuppression؛ SARS-COV2
سایر فایل های مرتبط با مقاله
مراجع
  1. Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison’s principles of internal medicine, 19e. New York: Mcgraw-hill: 2015.
  2. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011;6:330-6. PubMed PMID: 22879850; PubMed Central PMCID: PMCPMC3391953.
  3. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity. 2005;38:473-85. doi: 10.1080/08916930500285352. PubMed PMID: 16373252.
  4. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299-308. doi: 10.1097/01.md.0000091181.93122.55. PubMed PMID: 14530779.
  5. da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira T, Campos Alcantara R, Monteiro Arnozo G, et al. Clinical manifestations of COVID-19 in the general population: systematic review. Wien Klin Wochenschr. 2021;133:377-82. doi: 10.1007/s00508-020-01760-4. PubMed PMID: 33242148; PubMed Central PMCID: PMCPMC7689634.
  6. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27:1451-4. doi: 10.1038/s41418-020-0530-3. PubMed PMID: 32205856; PubMed Central PMCID: PMCPMC7091918.
  7. Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell. 2021;184:1671-92. doi: 10.1016/j.cell.2021.02.029. PubMed PMID: 33743212; PubMed Central PMCID: PMCPMC7885626.
  8. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72-3. doi: 10.5582/bst.2020.01047. PubMed PMID: 32074550.
  9. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279-83. doi: 10.1016/j.jcrc.2020.03.005. PubMed PMID: 32173110; PubMed Central PMCID: PMCPMC7270792.
  10. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71:1400-12. doi: 10.1002/art.40930. PubMed PMID: 31385462; PubMed Central PMCID: PMCPMC6827566.
  11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928. PubMed PMID: 9324032.
  12. Organization(WHO) WH. Global surveillance for COVID-19 caused by human infection with COVID-19 virus 2020. [cited 23 May 2020]. Available from: https://www.who.int/docs/default-source/coronaviruse/2020-03-20-surveillance.pdf?sfvrsn=e6be6ef1_2
  13. Gulsen A, Konig IR, Jappe U, Dromann D. Effect of comorbid pulmonary disease on the severity of COVID-19: A systematic review and meta-analysis. Respirology. 2021;26:552-65. doi: 10.1111/resp.14049. PubMed PMID: 33955623; PubMed Central PMCID: PMCPMC8207055.
  14. Pranata R, Soeroto AY, Huang I, Lim MA, Santoso P, Permana H, et al. Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19. Int J Tuberc Lung Dis. 2020;24:838-43. doi: 10.5588/ijtld.20.0278. PubMed PMID: 32912389.
  15. Kaltsas A, Sepkowitz K. Community acquired respiratory and gastrointestinal viral infections: challenges in the immunocompromised host. Curr Opin Infect Dis. 2012;25:423-30. doi: 10.1097/QCO.0b013e328355660b. PubMed PMID: 22766648.
  16. Memoli MJ, Athota R, Reed S, Czajkowski L, Bristol T, Proudfoot K, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis. 2014;58:214-24. doi: 10.1093/cid/cit725. PubMed PMID: 24186906; PubMed Central PMCID: PMCPMC3871797.
  17. Mandl JN, Ahmed R, Barreiro LB, Daszak P, Epstein JH, Virgin HW, et al. Reservoir host immune responses to emerging zoonotic viruses. Cell. 2015;160:20-35. doi: 10.1016/j.cell.2014.12.003. PubMed PMID: 25533784; PubMed Central PMCID: PMCPMC4390999.
  18. D’Antiga L. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. Liver Transpl. 2020;26:832-4. doi: 10.1002/lt.25756. PubMed PMID: 32196933.
  19. Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018;18:e217-e27. doi: 10.1016/S1473-3099(18)30127-0. PubMed PMID: 29680581; PubMed Central PMCID: PMCPMC7164784.
  20. Minotti C, Tirelli F, Barbieri E, Giaquinto C, Dona D. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. J Infect. 2020;81:e61-e6. doi: 10.1016/j.jinf.2020.04.026. PubMed PMID: 32335173; PubMed Central PMCID: PMCPMC7179496.
آمار
تعداد مشاهده مقاله: 1,758
تعداد دریافت فایل اصل مقاله: 1,957


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب